ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0902

Does Imaging of the Sacroiliac Joint and Spine Differ in Patients Presenting with Undiagnosed Back Pain and Psoriasis, Acute Anterior Uveitis, and Colitis: An Inception Cohort Study

Walter Maksymowych1, Ulrich Weber2, Jonathan Chan3, Raj Carmona4, James Yeung5, Sibel Zehra Aydin6, Jodie Reis7, Liam Martin8, Ariel Masetto9, Olga Ziouzina8, Dianne Mosher8, Stephanie Keeling10, Sherry Rohekar11, Rana Dadashova12, Joel Paschke12, Amanda Carapellucci12 and Robert Lambert13, 1Department of Medicine, University of Alberta, Alberta, Canada, Edmonton, AB, Canada, 2Practice Buchsbaum Schaffhausen, Schaffhausen, Switzerland, 3University of British Columbia, Vancouver, BC, Canada, 4St. Joseph's Healthcare Hamilton, Mississauga, ON, Canada, 5James Yeung Rheumatology, Richmond, BC, Canada, 6University of Ottawa , Faculty of Medicine, Rheumatology, Ottawa, ON, Canada, 7Polmed Research Inc, Saskatoon, Canada, 8University of Calgary, Calgary, AB, Canada, 9Universite de Sherbrooke, Sherbrooke, QC, Canada, 10Division of Rheumatology, University of Alberta, Edmonton, AB, Canada, 11University of Western Ontario - London, London, ON, Canada, 12CARE Arthritis, Edmonton, AB, Canada, 13University of Alberta, Edmonton, AB, Canada

Meeting: ACR Convergence 2021

Keywords: Ankylosing spondylitis (AS), Diagnostic, MRI

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster II: Imaging in Spondyloarthritis (0897–0907)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Diagnosis and classification of axial spondyloarthritis (axSpA) relies considerably on imaging evidence of sacroiliitis which has led to the development of classification criteria which also rely on imaging. However, it has been suggested that such criteria may not be appropriate for axSpA patients presenting with other forms of SpA, especially psoriatic, because imaging features may vary in frequency and/or may be atypical. This hypothesis has never been tested in a prospective inception cohort of patients presenting with undiagnosed back pain. We aimed to compare the spectrum of radiographic and MRI abnormalities in the sacroiliac joint (SIJ) and spine of an inception cohort of patients presenting with undiagnosed back pain and psoriasis, iritis, and colitis.

Methods: We used data from the prospective multicenter Screening for Axial Spondyloarthritis in Psoriasis, Iritis, and Colitis (SASPIC) Study, which is aimed at early detection of axial SpA in patients referred by the respective specialist after first presenting with these disorders. Consecutive patients ≤45 years of age with ≥3 months undiagnosed back pain with any one of psoriasis, AAU, or colitis undergo routine clinical evaluation by a rheumatologist for axial SpA followed by imaging. In SASPIC I, MRI evaluation of the SIJ and whole spine was ordered per rheumatologist decision. In SASPIC II, MRI evaluation of the SIJ was ordered for all patients. Radiographs and MRI scans were assessed by two central readers and comparisons of the three groups were based on concordant assessments of imaging features. Evaluation of MRI scans included both global assessment for presence/absence of axSpA with confidence scale (-10 to +10), active and structural lesions typical of axSpA per recent ASAS definitions, and granular assessment of individual lesions according to SIJ quadrants and halves in consecutive semicoronal slices through the SIJ as well as detailed evaluation of active and structural lesions in individual discovertebral units of the spine on consecutive sagittal slices. Groups were compared by ANOVA and the chi-square test.

Results: A total of 240 patients were recruited, 143 from SASPIC I and 97 from SASPIC II, 101 (42.1%) being diagnosed with axSpA (65.3% male, mean age 34.4 years, mean symptom duration 8.7 years, B27 positive 55.4%). Mean age of colitis (N=101), psoriasis (N=61), iritis (N=78) patients were 33.4, 36.6, 34.3 years, respectively, mean symptom duration was 6.8, 7.2, 9.4 years, respectively, and % males were 45.5%, 52.5%, 51.3%, respectively. MRI scans of the SIJ were available in 101 patients and of these 41 also had MRI of the spine. There were no significant group differences for unilateral versus bilateral radiographic sacroiliitis and no significant differences in the frequencies, type, or distribution of MRI lesions in the SIJ and spine(Table). In particular, there was not a single case where there was an MRI indicative of axSpA in the spine that was not also evident in the SIJ.

Conclusion: Data from the SASPIC prospective inception cohort does not support the view that imaging of the SIJ and spine differs in psoriatic axSpA, which appears similar to axSpA associated with iritis or colitis. These data support the umbrella concept of axSpA.


Disclosures: W. Maksymowych, AbbVie, 2, 5, 6, Bristol-Myers Squibb, 2, 5, Boehringer Ingelheim, 2, Celgene, 2, 5, Eli Lilly, 2, 5, Galapagos, 2, 5, Janssen, 6, Novartis, 2, 5, 6, Pfizer Inc, 2, 5, 6, UCB, 2, 5, 6; U. Weber, None; J. Chan, Pfizer, 5, Abbvie, 5, UCB, 2, 5, Novartis, 2, 5, 6, Janssen, 2, 6, Eli Lilly, 2, 6, Sandoz, 2, Roche, 2, Gilead, 2, Merck, 2, Fresenius Kabi, 2; R. Carmona, None; J. Yeung, None; S. Aydin, Abbvie, 6, Celgene, 6, UCB, 6, Novartis, 6, Jannsen, 6, Pfizer, 6, Sanofi, 6; J. Reis, None; L. Martin, None; A. Masetto, AbbVie, 2, 5, 6, BMS, 2, 5, 6, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, Sanofi, 2, 5, 6, UCB, 2, 5, 6, Eli Lilly, 2, 5, 6, Janssen, 2, 5, 6, Amgen, 5, Merck, 5, Teva, 5; O. Ziouzina, None; D. Mosher, None; S. Keeling, AbbVie, 1, 6, Amgen, 2, Pfizer, 2, 5, AstraZeneca, 2, UCB, 2, 6, Janssen, 2, 6, Sandoz, 2, 5, 6, Merck, 2, 5, GSK, 2, FresniusKabi, 2, Eli Lilly, 2, Novartis, 2; S. Rohekar, None; R. Dadashova, None; J. Paschke, None; A. Carapellucci, None; R. Lambert, Pfizer, 2.

To cite this abstract in AMA style:

Maksymowych W, Weber U, Chan J, Carmona R, Yeung J, Aydin S, Reis J, Martin L, Masetto A, Ziouzina O, Mosher D, Keeling S, Rohekar S, Dadashova R, Paschke J, Carapellucci A, Lambert R. Does Imaging of the Sacroiliac Joint and Spine Differ in Patients Presenting with Undiagnosed Back Pain and Psoriasis, Acute Anterior Uveitis, and Colitis: An Inception Cohort Study [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/does-imaging-of-the-sacroiliac-joint-and-spine-differ-in-patients-presenting-with-undiagnosed-back-pain-and-psoriasis-acute-anterior-uveitis-and-colitis-an-inception-cohort-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/does-imaging-of-the-sacroiliac-joint-and-spine-differ-in-patients-presenting-with-undiagnosed-back-pain-and-psoriasis-acute-anterior-uveitis-and-colitis-an-inception-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology